Tivic Health Systems, Inc. (TIVC) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Tivic Health Systems, Inc.'s filing signal turned positive.

Tivic Health Systems, Inc. has strategically transformed into a late-stage biopharmaceutical company focused on its Toll-like Receptor 5 (TLR5) agonist franchise, primarily Entolimod, for Acute Radiation Syndrome (ARS) and oncology indications. In February 2025, the company secured exclusive worldwide license rights to Entolimod and its second-generation compound, Entolasta, from Statera Biopharma. To support its biopharmaceutical development, Tivic established Velocity Bioworks, a contract development and manufacturing organization (CDMO), in December 2025. This pivot involved exiting its consumer healthtech business and suspending bioelectronic product development to concentrate resources on Entolimod. The company's lead program, Entolimod, has received Fast Track and Orphan Drug designations from the FDA for ARS.

Revenue is expected to be driven by the development and potential procurement of Entolimod for Acute Radiation Syndrome by government agencies, and by expanding Entolimod's applications into oncology indications like neutropenia. The CDMO business, Velocity Bioworks, is also intended to generate revenue by providing services to third-party customers.